CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Prestige Biopharma Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Prestige Biopharma Ltd
21 Biopolis Road
#04-24/28 Nucleos South Building
Phone: +65 69246535p:+65 69246535 138567  Singapore Ticker: 950210950210
Business Summary
Prestige Biopharma Ltd is a Singapore-based biopharmaceutical company. The Company is focused on the development of biosimilars and antibody drugs as well as vaccines for infectious diseases. Its biosimilar portfolio consists of over 12 pipelines, including HD201 (trastuzumab) in Phase III, HD204 (bevacizumab) in Phase III, and PBP1502 (adalimumab) in Phase I. Its antibody therapeutic portfolio includes PBP1510, PBP1710, IDC001, IDC005, IDC007, IDC008 and others. PBP1510 specifically binds pancreatic adenocarcinoma upregulated factor (PAUF), a protein that drives cancer cells to spread through blood flow and to escape immune recognition and exerts anti-metastasis and immune modulation effects. PBP1710 specifically binds to collagen triple helix repeat containing 1 (CTHRC1), a protein that facilitates cancer cells and exerts anti-metastasis and anti-tumor growth effects. IDC001 is designed to treat cancers that express high level of PAUF and CTHRC1.
(Source: 10-K405)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/20236/30/2023Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research
2834 Pharmaceutical preparations
2836 Biological products, except diagnostic substances

General Information
Outstanding Shares: 12,019,231 (As of 12/31/2023)
Shareholders: 40,726
Stock Exchange: KRX
Fax Number: +65 69242053


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, April 25, 2024